Relmada Therapeutics Stock Analysis

Relmada Stock Analysis Notes

About 17.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.93. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Relmada Therapeutics recorded a loss per share of 2.51. The entity last dividend was issued on the 30th of September 2019. The firm had 1:4 split on the 30th of September 2019. Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases and other disorders. The company was founded in 2004 and is headquartered in Coral Gables, Florida. Relmada Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people. To find out more about Relmada Therapeutics contact MBA MBA at 786 629 1376 or learn more at https://www.relmada.com.

Relmada Therapeutics Investment Alerts

Relmada Therapeutics Upcoming and Recent Events

Relmada Largest EPS Surprises

View All Earnings Estimates

Relmada Stock Institutional Investors

Note, although Relmada Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Relmada Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 20.76 M.

Relmada Profitablity

Management Efficiency

Relmada Therapeutics has return on total asset (ROA) of (0.8824) % which means that it has lost $0.8824 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6026) %, meaning that it created substantial loss on money invested by shareholders. Relmada Therapeutics' management efficiency ratios could be used to measure how well Relmada Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of July 23, 2025, Return On Tangible Assets is expected to decline to -1.83. The current year's Return On Capital Employed is expected to grow to -2.24. At present, Relmada Therapeutics' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 169.6 M, whereas Non Current Assets Total are forecasted to decline to about 20.9 K.

Technical Drivers

As of the 23rd of July, Relmada Therapeutics holds the Coefficient Of Variation of 684.28, risk adjusted performance of 0.1412, and Semi Deviation of 9.55. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Relmada Therapeutics, as well as the relationship between them. Please check Relmada Therapeutics treynor ratio, as well as the relationship between the downside variance and kurtosis to decide if Relmada Therapeutics is priced some-what accurately, providing market reflects its current price of 0.63 per share. As Relmada Therapeutics is a penny stock we also suggest to check out its total risk alpha numbers.

Relmada Therapeutics Price Movement Analysis

Relmada Therapeutics Insider Trading Activities

Relmada Therapeutics Outstanding Bonds

Relmada Therapeutics Predictive Daily Indicators

Relmada Therapeutics Forecast Models

Relmada Therapeutics' time-series forecasting models are one of many Relmada Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Relmada Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Relmada Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Relmada shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Relmada Therapeutics. By using and applying Relmada Stock analysis, traders can create a robust methodology for identifying Relmada entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Relmada analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Relmada analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Relmada Therapeutics stock analysis indicators help investors evaluate how Relmada Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Relmada Therapeutics shares will generate the highest return on investment. By understating and applying Relmada Therapeutics stock analysis, traders can identify Relmada Therapeutics position entry and exit signals to maximize returns.

When running Relmada Therapeutics' price analysis, check to measure Relmada Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relmada Therapeutics is operating at the current time. Most of Relmada Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relmada Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relmada Therapeutics' price. Additionally, you may evaluate how the addition of Relmada Therapeutics to your portfolios can decrease your overall portfolio volatility.